Utility of PET in Breast Cancer

Area of Science:

• Oncology
• Nuclear Medicine
• Radiology

Background:

• Breast cancer is a leading cause of cancer death in women, with early detection crucial for curability.
• Mammography is a primary screening tool, but limitations exist in diagnosing and staging breast cancer accurately.
• Positron emission tomography (PET) offers metabolic imaging to overcome diagnostic and staging challenges.

Purpose of the Study:

• To evaluate the role of F-18 fluorodeoxyglucose (FDG) PET in breast cancer diagnosis, staging, and treatment monitoring.
• To highlight the clinical utility of FDG-PET in identifying metastatic axillary lymph nodes and assessing treatment response.

Main Methods:

• Utilizing F-18 fluorodeoxyglucose (FDG) as a radiotracer for PET imaging.
• Employing whole-body PET imaging for comprehensive staging of breast cancer patients.
• Analyzing metabolic signals from tumor tissue to assess chemotherapy effects.

Main Results:

• FDG-PET can detect breast cancers larger than 1 cm in diameter.
• It accurately identifies axillary lymph node metastases in locally advanced disease.
• FDG-PET effectively differentiates between chemotherapy responders and nonresponders early in treatment.

Conclusions:

• FDG-PET is a valuable tool for accurate breast cancer staging and early detection.
• Metabolic imaging with FDG-PET enables monitoring of chemotherapy response.
• Identifying nonresponders via FDG-PET can help personalize treatment, reducing toxicity and improving outcomes.